bioavailability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
NMR spectroscopy is one of the principal techniques used to obtain physical, chemical, electronic and structural information about molecules due to the chemical shift of the resonance frequencies of the nuclear spins in the sample. Peak splittings due to J- or dipolar couplings between nuclei are also useful. NMR spectroscopy can provide detailed and quantitative information on the functional groups, topology, dynamics and three-dimensional structure of molecules in solution and the solid state. Since the area under an NMR peak is usually proportional to the number of spins involved, peak integrals can be used to determine composition quantitatively. A common methodology involves an extended delay time between each spectral scan (generally, 5 times the longest T1 in a complex mixture for a 90 degree pulsing angle, where T1 can be calculated using techniques such as FLIPS). This lets nuclei relax completely, allowing integrals to be more accurate for quantitation. Structure and molecular dynamics can be studied (with or without "magic angle" spinning (MAS)) by NMR of quadrupolar nuclei (that is, with spin S > 1/2) even in the presence of magnetic "dipole-dipole" interaction broadening (or simply, dipolar broadening), which is always much smaller than the quadrupolar interaction strength because it is a magnetic vs. an electric interaction effect. Additional structural and chemical information may be obtained by performing double-quantum NMR experiments for pairs of spins or quadrupolar nuclei such as 2H.
=== Regulation of cholesterol synthesis === Biosynthesis of cholesterol is directly regulated by the cholesterol levels present, though the homeostatic mechanisms involved are only partly understood. A higher intake of food leads to a net decrease in endogenous production, whereas a lower intake of food has the opposite effect. The main regulatory mechanism is the sensing of intracellular cholesterol in the endoplasmic reticulum by the protein SREBP (sterol regulatory element-binding protein 1 and 2). In the presence of cholesterol, SREBP is bound to two other proteins: SCAP (SREBP cleavage-activating protein) and INSIG-1. When cholesterol levels fall, INSIG-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the Golgi apparatus. Here SREBP is cleaved by S1P and S2P (site-1 protease and site-2 protease), two enzymes that are activated by SCAP when cholesterol levels are low. The cleaved SREBP then migrates to the nucleus and acts as a transcription factor to bind to the sterol regulatory element (SRE), which stimulates the transcription of many genes. Among these are the low-density lipoprotein (LDL) receptor and HMG-CoA reductase. The LDL receptor scavenges circulating LDL from the bloodstream, whereas HMG-CoA reductase leads to an increase in endogenous production of cholesterol. A large part of this signaling pathway was clarified by Dr. Michael S. Brown and Dr. Joseph L. Goldstein in the 1970s. In 1985, they received the Nobel Prize in Physiology or Medicine for their work.
During the 2025 legislative session, Moore introduced the Housing for Jobs Act, a bill that would require local governments to automatically approve new housing developments in areas where there are 1.5 jobs for every available housing unit. After the Maryland Association of Counties expressed concerns with the bill, House lawmakers rewrote the bill that requires the state's housing secretary to set a 10-year target for housing production in the state and creates a commission to study the state's housing crisis and develop recommendations on how to address the lack of affordable housing in the state. However, this version of the bill failed to pass the General Assembly. In August 2025, Moore signed an executive order incentivizing the Maryland Department of General Services and the Maryland Department of Transportation to use their available land for housing and accelerate land awards to developers, creates housing production targets for Maryland counties, and instructs all state agencies that use housing-related permits to draft and implement plans to speed up and increase transparency around permit application processing. In January 2026, Moore said he would support three bills to spur construction and increase housing in Maryland, including proposals to encourage mixed-use development projects on state-owned land at train stations and give Maryland developers "early vesting", which would lock in a project's ground rules for five years.
Sources: en.wikipedia.org
=== Bibliography === Jamaluddin, Ahmad Badawi (2007). PENGGUNAAN UBATAN TRADISIONAL DI PASAR TAMU DAN PASAR BESAR DAERAH TAWAU, SABAH: SATU TINJAUAN [USE OF TRADITIONAL MEDICINE IN WEEKLY MARKET AND MAIN MARKET IN TAWAU DISTRICT, SABAH: A REVIEW] (PDF). Conservation Biology Program School of Science and Technology (Thesis) (in Malay). pp. 1–27. Archived (PDF) from the original on 2 June 2025. Retrieved 2 June 2025 – via Universiti Malaysia Kelantan. Kustiariyah (2007). "TERIPANG SEBAGAI SUMBER PANGAN DAN BIOAKTIF" [SEA CUCUMBER AS A FOOD AND BIOACTIVE SOURCE]. Indonesian Journal of Aquatic Product Technology [Buletin Teknologi Hasil Perikanan] (in Indonesian). X (1): 1–8. Archived from the original on 1 June 2025. Damaiyanti, Dian Widya (2015). "Karakterisasi Esktrak Air Teripang Emas (Stichopus hermanii)" [Characterization Of Water Extract Gold Sea Cucumber (Stichopus hermanii)]. Denta (Jurnal Kedokteran Gigi) (in Indonesian). 9 (1): 1–8. ISSN 1907-5987. Archived from the original on 2 June 2025. Text is licensed by DENTA (Journal Kedokteran Gigi) under CC BY-NC-SA 4.0 Vaitilingon, Devarajen; Smith, Stuart; Watson, Guy; Miller, Tim; Alattas, Syed; Ong Hock, Keat; Zainoddin, Jamari; Zaidnuddin, Ilias; Azhar, Hamzah (2016). "Sea cucumber hatchery seed production in Malaysia: From research and development, to pilot-scale production of the sandfish Holothuria scabra" (PDF). SPC Beche-de-mer Information Bulletin (36): 67–75. Archived from the original (PDF) on 16 May 2021 – via Sustainable Aquaculture Research & Development (Mauritius).
=== Fluorescent detection === Fluorescence spectroscopy is one of the most common droplet detection techniques. It provides a rapid response, and, for applicable analytes, it has a strong signal. The use of fluorescence spectroscopy in microfluidics follows a similar format to most other fluorescent analytical techniques. A light source is used to excite analyte molecules in the sample, after which the analyte fluoresces, and the fluorescence response is the measured output. Cameras can be used to capture the fluorescence signal of the droplets, and filters are often used to filter out scattered excitation light. In microfluidic droplet detection, the experimental setup of a fluorescence instrument can vary greatly. A common setup in fluorescent droplet detection is with the use of an epifluorescence microscope. This sometimes utilizes a confocal geometry, which can vary depending on experimental needs. For example, Jeffries et al. reported success with exploring an orthogonal confocal geometry, as opposed to a standard epi geometry. However, other setups for fluorescence detection have been explored, as epifluorescence microscopes can be expensive and difficult to upkeep. Cole et al. have proposed and tested an experimental setup with fiber optics to conduct fluorescence analysis of microfluidic droplets. Fluorescence detection of droplets has a number of advantages. First, it can accommodate a large and fast throughput. Analysis of thousands of samples can be conducted in a short period of time, which is advantageous for the analysis of a large number of samples.
Moreover, although it has been established that ethanol modulates ion channels to mediate its effects, ion channels are complex proteins, and their interactions and functions are complicated by diverse subunit compositions and regulation by conserved cellular signals (e.g. signaling lipids). Alcohol is also converted into phosphatidylethanol (PEth, an unnatural lipid metabolite) by phospholipase D2. This metabolite competes with PIP2 agonist sites on lipid-gated ion channels. The result of these direct effects is a wave of further indirect effects involving a variety of other neurotransmitter and neuropeptide systems. This presents a novel indirect mechanism and suggests that a metabolite, not the ethanol itself, could cause the behavioural or symptomatic effects of alcohol intoxication. Many of the primary targets of ethanol are known to bind PIP2 including GABAA receptors, but the role of PEth needs to be investigated further.
=== Dietary sources === Aspartic acid is not an essential amino acid, which means that it can be synthesized from central metabolic pathway intermediates in humans, and does not need to be present in the diet. In eukaryotic cells, roughly 1 in 20 amino acids incorporated into a protein is an aspartic acid, and accordingly almost any source of dietary protein will include aspartic acid. Additionally, aspartic acid is found in:
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.